ProBDNF and its receptors in immune-mediated inflammatory diseases: novel insights into the regulation of metabolism and mitochondria

Immune-mediated inflammatory diseases (IMIDs) consist of a common and clinically diverse group of diseases. Despite remarkable progress in the past two decades, no remission is observed in a large number of patients, and no effective treatments have been developed to prevent organ and tissue damage....

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1155333
Main Authors Li, Qiao, Hu, Yue-Zi, Gao, Shan, Wang, Peng-Fei, Hu, Zhao-Lan, Dai, Ru-Ping
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 18.04.2023
Subjects
Humans
immune-mediated inflammatory diseases
Immunology
Immunomodulating Agents
metabolism
mitochondria
p75NTR
ProBDNF
Receptor, Nerve Growth Factor - metabolism
sortilin
ProBDNF
p75NTR
sortilin
immune-mediated inflammatory diseases
metabolism
mitochondria
Online AccessGet full text

Cover

More Information
Summary:Immune-mediated inflammatory diseases (IMIDs) consist of a common and clinically diverse group of diseases. Despite remarkable progress in the past two decades, no remission is observed in a large number of patients, and no effective treatments have been developed to prevent organ and tissue damage. Brain-derived neurotrophic factor precursor (proBDNF) and receptors, such as p75 neurotrophin receptor (p75 ) and sortilin, have been proposed to mediate intracellular metabolism and mitochondrial function to regulate the progression of several IMIDs. Here, the regulatory role of proBDNF and its receptors in seven typical IMIDs, including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, allergic asthma, type I diabetes, vasculitis, and inflammatory bowel diseases, was investigated.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Alexander G. Gabibov, Institute of Bioorganic Chemistry (RAS), Russia; Changwei Wei, Beijing Chaoyang Hospital, Capital Medical University, China
These authors have contributed equally to this work
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Edited by: Michael R. Elliott, University of Virginia, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1155333